We would love to hear your thoughts about our site and services, please take our survey here.
I have been surprised previously on the release of positive RNS the share price has fallen. We have struggled to see that £2 ceiling been broken and have had a lack of information due to the NDA.
However the news articles over the weekend now show how close we are and how big this could be.
These articles in national and now international sites are starting to bring the Avacta name and potential to far more investors.
I expect us to break the £2 ceiling tomorrow.
I am heavily invested and am here for the longer term cancer treatments, however I have increased my holding based on the covid tests and would like to realise some profit shorter term.
The real catalyst will be a RNS on LFT, TU or Boris.
I see tomorrow as a last possibility to load up further below £2.50, but I have been wrong before, however time tell. Looking forward to 7am and 8am and Boris opening up pla..
GLA
Another article in the Mail this morning naming Avacta with a Game Changer 5min LFT opening the economy. First photo in the article is a picture of Sir Al.
https://mol.im/a/9281337
Role on tomorrow to see how the share price reacts and hopefully our TU later in the week to provide some more clarity and further support our share price increase.
GLA
The press are finally waking up to Avacta. We are named and mentioned in the Daily Mail this morning regarding Boris releasing lockdown. Yorkshire biotech firm Avacta's 5 minute LFT that is better performing than the current American (china) LFD tests and will enable the re opening of theatres and sporting events. It also mentions the report in the Huffington Post and operation Moonshot.
Like many others have bought and held these for a year and the months of holding and holding my nerve with the fluctuating
share price has certainly paid off. The next few months are going to be fantastic. Its many years since I have had a sleepless night because I'm so excited.
GLA
I believe that Avacta delayed the trading update until after they released the performance of the LFD, as this is the key catalyst for progressing and setting numbers regarding manufacturing contracts, government contracts and potential sales etc. I would now expect we are going into a period of transformational regular positive updates that will see the share price continue to increase over the next few months.
A very exciting time to be invested in Avacta and a great reward for those that kept the faith.
Arise Sir Alistair, what results. Its been along wait but its been worth it . Avacta have deliver a fantastic LFD that all will want to build and buy. Great results for long term holders that maintained the faith.
£2.33
Great RNS from Avacta to break the silence and update shareholders where we are with the LFD. Many positives with another manufacturer on board and role out and supply beyond UK. We know we are no longer just reliant on uk government. Mologic help open us up to world wide markets, on their website work with Bill Gates Foundation etc.
Great to get definite timeliness for getting LFD to market and when we can expect further updates.
I agree that Avacta owe shareholders an update, as we are all in the dark over our covid tests. Expectations and timescales were built up by the RNS's and follow up interviews. I along with many others have invested and built up our investment in Avacta based on news directly from the company. One thing that stood out to me when first investing in Avacta, was that the CEO was a straight talking Yorkshire man who delivered regular clear positive message's.
At the end of last year we continued to get messages about how pleased we are with the LFD saliva test, to then get a RNS stating its now a Nasal Swab. Since then nothing on our LFD test progress apart from we now have a name for it.
We guess that its now nasal swab because that's the government's prefered method. We guess that the CEO interviews and one liners at the end of RNS's on LFD progress and that he is looking forward to updating us soon, have dried up because of an NDA with the government and because we are being lined up to produce the UK sovereign test.
We have endless posts day after day, week after week and now month after month speculating what the silence means
, whats S&S going to be and the quality of the tests, when they are going to be available, how many can be produced, who we are working with, are we still working with Cytiva etc etc.
Everyone is clambering for some information and is reading something into any information available. The government contract is delayed, is it because they are waiting for Avacta. Medusa change their website or set up manufacturing capability then our test is nearly there. Avacta change their website its obviously another sign.
My biggest concern is if we are investing all our efforts into working with UK government and find they have a change of policy or ditch us for another company at the end of months of collaboration. We see contracts awarded to friends and contacts of government ministers. Matt Han****s local landlord got a multi million pound contract for delivering PPE, probably agreed over a couple of pints during a lock in. We only need the Prime Ministers cousin to get a job for Innova and we could be kicked into the long grass.
I am sure that the silence from Avacta is for very good reason and many of the posts on here following some detective and guess work are no far off. But I am finding it increasingly frustrating, particularly as to how free flowing the positive updates had previously been. I continue to hold and look forward to Alistair Smith walking out with Boris to the press briefing to update the public on Avacta's worlds best sovereign UK Affimer test.
Whilst I initially invested in Avacta because of the cancer treatments and the unique Affimer technology, I increased my holding substancially based on the regular very positive RNS around Covid 19 testing from Avacta, quotes about aiming for best tests, positive timescales reference to BAMs and LFD. RNS's were back up with video interviews all confirming and building expectations.
I continued to build my position based of information released by Avacta over last summer.
Whilst I admit I don't understand fully the complexities of producing the the covid 19 testing and rushing the new Affimer technology to market , I am feeling increasing frustrated by Avacta silence and feel investors deserve an update.
Whilst I understand the potential NDA and working with the UK government regarding a sovereign testing capability, I don't trust the government and their handling the pandemic, they have a history of making u turns. If they find that vaccines prevent the spread, they could well ditch Moonshot.
Whilst I am pleased to see very positive RNS's regarding collaboration partnerships with larger pharmaceutical companies utilising the Affimer technology , it does not answer alot of the outstanding questions over the substantial delays with both BAMs and LFD. I would like to know why we are now looking at nasal swabs for LFD, is Saliva LFD now ditched or is that still an option.
I am putting my thoughts on here not to directly critise Avacta for delays as they are working incredible hard to deliver and of course there are many other companies involved to bring tests to market. However the silence is very damaging.
Time will tell whether Avacta can deliver on their covid testing and if they do my blood pressure will improve and we will all forget the months of frustrating silence. I continue to hold and hope that news is not far away.
I think its time for you to grow up and take responsibility for you own investment decisions.
I have filtered you so don't have to read your targeted posts. I enjoy reading Richken's posts and I agree with his positivity regarding Avacta, but I don't expect him to tell me when to buy, sell or provide evidence of how many shares he owns.
GLA
An article this morning in the Mail highlights that Heathrow Airport has a current Covid testing centre set up which costs £150 and takes 30 minutes. The article highlights that they are working with Oxford and Manchester universities with the testing of 3 other tests , that are much cheaper and quicker.
The article states one of the tests is a saliva based test similar to a pregnancy test with results that come back in 10 minutes.
I wonder who that could be?
Not long to wait now
GLA
Another fantastic interview with further evidence on the progress that Avacta are making on all fronts. Confirmation of how well the tests are performing and expected market and the need for further manufactures.
I have never been so excited to be in invested in a company.
GLA
Another positive step and further demonstration of the professional and controlled way that Avacta are moving the LFD forward. We are moving forward at some pace and all looks well for having our finished certified product before large second winter spike.
Well done Avacta.
BBI Solutions has served the global diagnostics industry for over 50 years, as a leading developer and manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market.
Over the past 50 years, BBI has grown from a small specialist company, to a global business with manufacturing sites in five different countries, spanning three continents.
Our product ranges include:
Biological Raw Materials
Antigens
Enzymes
Monoclonal Antibodies and
Recombinant Fab Antibodies
Serum & Plasma Products
Depleted Serum
Disease State Plasma
Normal Serum and
Patient Samples
In addition, we manufacture world renowned labels for lateral flow, ELISA assay and biosensors, these include:
Gold Nanoparticles
Horseradish Peroxidase and
Glucose Oxidase
BBI Solutions also offers end to end Contract Development and manufacturing services, with a core focus on custom gold conjugation and lateral flow test manufacture.
Innovative new projects include the integration of emerging technologies into our products, such as the Novarum Smartphone Reader.
BBI Solutions is part of the BBI Group www.the-bbigroup.com
Avacta Group plc
("Avacta" or "the Group" or "the Company")
COVID-19 Rapid Antigen Test Manufacturing Partner
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has appointed BBI Solutions, part of BBI Group ("BBI"), to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cytiva.
BBI Solutions is a leading global developer and manufacturer of raw materials and finished test products for the in-vitro diagnostics market, with manufacturing sites in five different countries, spanning four continents.
The manufacturing agreement between Avacta and BBI comprises the accelerated development and validation of a scaled-up manufacturing process that has the potential to ramp up to a production capacity of millions of tests per month. Avacta, Cytiva and BBI are in the process of the technology transfer of the prototype and related manufacturing procedures for the saliva-based rapid
SARS-CoV-2 antigen test from Cytiva to BBI.
Avacta aims to begin clinical validation of the test as soon as possible by using the first pilot batches generated as part of the technology transfer process for these studies. In parallel with these clinical validation studies, which will be run within the UK government's CONDOR programme and potentially with other collaborators globally, BBI will work with Avacta and Cytiva to produce the additional technical documentation that is required for CE marking of the final product.
Dr. Alastair Smith, Chief Executive of Avacta Group commented:
"I am delighted to be working with BBI to manufacture the rapid COVID-19 test. BBI has been excellent to work with to define a highly compressed product development timeline that will allow us to get the product to market as quickly as possible.
We anticipate very high demand for the COVID-19 rapid test and will be working with our preferred manufacturing partners at BBI to satisfy that demand. We are actively continuing our discussions with other manufacturing partners to ensure that we have access to additional manufacturing capacity to address the global need for SARS-CoV-2 antigen testing both now, and in the next few years.
As we set out in the use of proceeds at the recent fund raising, we have now expanded our product development team with the appointment of an experienced in-vitro diagnostic Product Development Manager, and we are expanding the protein production facilities in order to meet the expected demand for Affimer proteins for the COVID-19 tests and future diagnostic tests in the pipeline.
The diagnostics business has also been working at a rapid pace towards ISO13485 accreditation, which will streamline CE marking and other regulatory approval processes.
I am immensely proud of what has been achieved by Avacta
Late trade taking it to £1.50
Jul 31 2020, 17:07
150.00
108,119
0.00
0.00
?
£162,178.5
O
This is massive news and a great RNS for long term holders.
Whatever news Avacta seem to release that is not directly related to LFD seems to get some criticism. Probably those that are currently underwater.
Alistiar Smith is growing the business and planting seeds that will reap rewards for those that see this as an investment.
This is also another confidence boost in the Affimer technology, another large pharmaceutical company is convinced, it certainly gives me further confidence.
GLA
Big Al is a tease and has given us something to dream about over the weekend. If Avacta end up supplying USA some of those large share predictions could become a reality.
GLA
This RNS tells us that the UK Government are desperate for Avacta to deliver, they are supporting us in its testing and they see us as a solution to their testing problems.
It will not just be the uk government but all are going to want us on board.
Just keep hold and watch it climb.
GLA
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Update on Clinical Validation of Adeptrix COVID-19 Diagnostic Test
Avacta to begin clinical validation of the high throughput COVID-19 laboratory test in collaboration with the UK government CONDOR programme
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has begun work with the UK government's CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry ("BAMSTM") laboratory assay developed with Adeptrix (Beverly, MA, USA).
The COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), recently funded by the National Institute for Health Research, UK Research and Innovation, Asthma UK and the British Lung Foundation, was created by the UK government to provide a route for evaluating new COVID-19 diagnostic tests in hospitals and in community healthcare settings.
Adeptrix's novel BAMS platform uses Affimer reagents to capture the virus and viral proteins from patient samples and combines this with the power of mass-spectrometry analysis to provide a highly sensitive and specific diagnostic test. Up to 1,000 nasopharyngeal swab or saliva samples per day can be analysed by a single technician using the BAMS assay, making it a very attractive high throughput technique for COVID-19 screening in the clinical setting.
Through the collaboration with the CONDOR scheme, Avacta will be provided access to patient samples and collaborators in UK hospitals to evaluate the performance of the prototype BAMS assay and to conduct the clinical validation study.
The work with the CONDOR programme will commence immediately to evaluate the test performance using real patient samples and will quickly progress to full clinical validation.
Dr. Alastair Smith, Chief Executive of Avacta Group commented:
"I am delighted that the COVID-19 BAMS assay that we are developing with Adeptrix has been accepted into the CONDOR programme. This provides us with access to patient samples and partners in UK hospitals to rapidly carry out the validation studies that are critical to progress the BAMS assay development.
We are confident that the BAMS assay will perform very well and potentially provide a new gold standard for laboratory reference testing for the COVID-19 infection. The BAMS assay runs on equipment that is already installed in most hospital clinical microbiology labs but is currently unused for COVID-19 testing. Therefore, with the potential for a single technician to analyse up to 1,000 samples a day, the BAMS assay will provide a significant boost to centralised hospital testing capacity around the world.
I am also very pleased that the CONDOR programme will support the clinical validation of the rapid saliva-based COVID-19 antigen test strip that we are developing with Cytiva. This, combined with